tiprankstipranks
United Therapeutics Corp. (UTHR)
NASDAQ:UTHR
US Market
UTHR
United Therapeutics
RESEARCH TOOLSreports
Want to see UTHR full AI Analyst Report?

United Therapeutics (UTHR) Stock Forecast & Price Target

741 Followers
See the Price Targets and Ratings of:

UTHR Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
United
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UTHR Stock 12 Month Forecast

Average Price Target

$670.44
▲(13.95% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $670.44 with a high forecast of $738.00 and a low forecast of $516.00. The average price target represents a 13.95% change from the last price of $588.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","514":"$514","739":"$739","401.5":"$401.5","626.5":"$626.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$738.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":670.4444444444445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$670.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":516,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$516.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,401.5,514,626.5,739],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,544.62,559.4953846153846,574.3707692307693,589.2461538461539,604.1215384615384,618.996923076923,633.8723076923077,648.7476923076923,663.623076923077,678.4984615384615,693.3738461538462,708.2492307692307,723.1246153846154,{"y":738,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,544.62,554.2988034188035,563.9776068376068,573.6564102564103,583.3352136752137,593.014017094017,602.6928205128205,612.371623931624,622.0504273504273,631.7292307692308,641.4080341880342,651.0868376068377,660.765641025641,{"y":670.4444444444445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,544.62,542.4184615384615,540.2169230769231,538.0153846153846,535.8138461538462,533.6123076923077,531.4107692307692,529.2092307692308,527.0076923076923,524.8061538461538,522.6046153846154,520.4030769230769,518.2015384615385,{"y":516,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":325.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":487.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":513.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":570.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":570.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":544.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$738.00Average Price Target$670.44Lowest Price Target$516.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
TD Cowen Analyst forecast on UTHR
Joseph Thome
TD Cowen
TD Cowen
$660→$675
Buy
14.72%
Upside
Reiterated
06/05/26
Morgan Stanley Analyst forecast on UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$516
Hold
-12.30%
Downside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Fate Therapeutics (NASDAQ: FATE) and Edgewise Therapeutics (NASDAQ: EWTX)
H.C. Wainwright Analyst forecast on UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$660
Buy
12.17%
Upside
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on UTHR
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$685
Buy
16.42%
Upside
Reiterated
05/20/26
J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on UTHR
Roger Song
Jefferies
Jefferies
$668→$733
Buy
24.58%
Upside
Reiterated
05/19/26
Jefferies Remains a Buy on United Therapeutics (UTHR)
Wells Fargo Analyst forecast on UTHR
Benjamin Burnett
Wells Fargo
Wells Fargo
$575→$738
Buy
25.43%
Upside
Upgraded
05/07/26
United Therapeutics upgraded to Overweight from Equal Weight at Wells FargoUnited Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
RBC Capital Analyst forecast on UTHR
Lisa Walter
RBC Capital
RBC Capital
$707→$701
Buy
19.14%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), United Therapeutics (NASDAQ: UTHR) and MannKind (NASDAQ: MNKD)
Raymond James Analyst forecast on UTHR
Tiago Fauth
Raymond James
Raymond James
$700
Buy
18.97%
Upside
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Bank of America Securities Analyst forecast on UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$569→$626
Hold
6.39%
Upside
Reiterated
03/30/26
Balanced View on Tyvaso’s IPF Upside: Strong Phase 3 Momentum Offset by Valuation and Execution Risks
Cantor Fitzgerald Analyst forecast on UTHR
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$525→$625
Buy
6.22%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on UTHR
Ashwani Verma
UBS
UBS
$655→$705
Buy
19.82%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on UTHR
Jasper Hellweg
Argus Research
Argus Research
$560
Buy
-4.82%
Downside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG Analyst forecast on UTHR
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/29/26
FDA premarket approval of LungFX positive for United Therapeutics, says LeerinkFDA premarket approval of LungFX positive for United Therapeutics, says Leerink
TD Cowen Analyst forecast on UTHR
Joseph Thome
TD Cowen
TD Cowen
$660→$675
Buy
14.72%
Upside
Reiterated
06/05/26
Morgan Stanley Analyst forecast on UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$516
Hold
-12.30%
Downside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Fate Therapeutics (NASDAQ: FATE) and Edgewise Therapeutics (NASDAQ: EWTX)
H.C. Wainwright Analyst forecast on UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$660
Buy
12.17%
Upside
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on UTHR
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$685
Buy
16.42%
Upside
Reiterated
05/20/26
J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)
Jefferies Analyst forecast on UTHR
Roger Song
Jefferies
Jefferies
$668→$733
Buy
24.58%
Upside
Reiterated
05/19/26
Jefferies Remains a Buy on United Therapeutics (UTHR)
Wells Fargo Analyst forecast on UTHR
Benjamin Burnett
Wells Fargo
Wells Fargo
$575→$738
Buy
25.43%
Upside
Upgraded
05/07/26
United Therapeutics upgraded to Overweight from Equal Weight at Wells FargoUnited Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
RBC Capital Analyst forecast on UTHR
Lisa Walter
RBC Capital
RBC Capital
$707→$701
Buy
19.14%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (NASDAQ: ONC), United Therapeutics (NASDAQ: UTHR) and MannKind (NASDAQ: MNKD)
Raymond James Analyst forecast on UTHR
Tiago Fauth
Raymond James
Raymond James
$700
Buy
18.97%
Upside
Initiated
04/09/26
United Therapeutics initiated with an Outperform at Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James
Bank of America Securities Analyst forecast on UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$569→$626
Hold
6.39%
Upside
Reiterated
03/30/26
Balanced View on Tyvaso’s IPF Upside: Strong Phase 3 Momentum Offset by Valuation and Execution Risks
Cantor Fitzgerald Analyst forecast on UTHR
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$525→$625
Buy
6.22%
Upside
Initiated
03/12/26
Cantor Fitzgerald Reaffirms Their Buy Rating on United Therapeutics (UTHR)
UBS Analyst forecast on UTHR
Ashwani Verma
UBS
UBS
$655→$705
Buy
19.82%
Upside
Assigned
03/05/26
Analysts Conflicted on These Healthcare Names: Veeva Systems (NYSE: VEEV) and United Therapeutics (NASDAQ: UTHR)
Argus Research Analyst forecast on UTHR
Jasper Hellweg
Argus Research
Argus Research
$560
Buy
-4.82%
Downside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
BTIG Analyst forecast on UTHR
Julian Harrison
BTIG
BTIG
―
Hold
―
Reiterated
02/25/26
Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

3 Months
Roanna RuizLeerink Partners
Success Rate
15/18 ratings generated profit
83%
Average Return
+15.56%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +15.56% per trade.
1 Year
Roger SongJefferies
Success Rate
12/13 ratings generated profit
92%
Average Return
+32.34%
Copying Roger Song's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +32.34% per trade.
2 Years
Jessica FyeJ.P. Morgan
Success Rate
22/22 ratings generated profit
100%
Average Return
+59.65%
Copying Jessica Fye's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +59.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTHR Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
10
22
21
24
15
Hold
7
11
11
9
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
33
32
33
20
In the current month, UTHR has received 15 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. UTHR average Analyst price target in the past 3 months is 670.44.
Each month's total comprises the sum of three months' worth of ratings.

UTHR Financial Forecast

UTHR Earnings Forecast

Next quarter’s earnings estimate for UTHR is $7.06 with a range of $6.07 to $8.59. The previous quarter’s EPS was $5.82. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s earnings estimate for UTHR is $7.06 with a range of $6.07 to $8.59. The previous quarter’s EPS was $5.82. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Sales Forecast

Next quarter’s sales forecast for UTHR is $807.68M with a range of $783.00M to $841.00M. The previous quarter’s sales results were $781.50M. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s sales forecast for UTHR is $807.68M with a range of $783.00M to $841.00M. The previous quarter’s sales results were $781.50M. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Stock Forecast FAQ

What is UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics Corp.’s 12-month average price target is 670.44.
    What is UTHR’s upside potential, based on the analysts’ average price target?
    United Therapeutics Corp. has 13.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is UTHR a Buy, Sell or Hold?
          United Therapeutics Corp. has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is United Therapeutics Corp.’s price target?
            The average price target for United Therapeutics Corp. is 670.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $738.00 ,the lowest forecast is $516.00. The average price target represents 13.95% Increase from the current price of $588.38.
              What do analysts say about United Therapeutics Corp.?
              United Therapeutics Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of UTHR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.